Publications
818 results found
Bower M, Palmieri C, Stebbing J, 2006, AIDS associated malignancies, Update on Cancer Therapeutics, Vol: 1, Pages: 221-234, ISSN: 1872-115X
There is a markedly increased risk of Kaposi's sarcoma, non-Hodgkin's lymphoma (NHL) and invasive cervical cancer during the course of infection with the human immunodeficiency virus (HIV). Therapy for these acquired immunodeficiency syndrome (AIDS) defining illnesses first involves anti-retroviral therapy to suppress HIV viremia and maintain CD4 counts. Subsequent chemotherapy is complicated by the underlying immunoparesis and options in the management of all three diseases are discussed herein. Improved understanding of their aetiopathogenesis will hopefully delineate new therapeutic options and strategies to control viral replication and virally induced diseases including malignancy. © 2006 Elsevier Ltd. All rights reserved.
Bower M, Mazhar D, Stebbing J, 2006, Should cervical cancer be an acquired immunodeficiency syndrome-defining cancer?, JOURNAL OF CLINICAL ONCOLOGY, Vol: 24, Pages: 2417-2419, ISSN: 0732-183X
- Author Web Link
- Cite
- Citations: 25
Rodger A, Stebbing J, Thompson AM, 2006, Breast cancer (non-metastatic)., Clin Evid, Pages: 2360-2392, ISSN: 1462-3846
Newcombe RG, Stebbing J, 2006, Quality of evidence published in clinical journals: signs of change?, POSTGRADUATE MEDICAL JOURNAL, Vol: 82, Pages: 355-356, ISSN: 0032-5473
Stebbing J, Crane J, Gaya A, 2006, Breast cancer (metastatic)., Clin Evid, Pages: 2331-2359, ISSN: 1462-3846
Stebbing J, Sanitt A, Nelson M, et al., 2006, A prognostic index for AIDS-associated Kaposi's sarcoma in the era of highly active antiretroviral therapy, LANCET, Vol: 367, Pages: 1495-1502, ISSN: 0140-6736
- Author Web Link
- Cite
- Citations: 69
Stebbing J, Bower M, Holmes P, et al., 2006, A single centre cohort experience with a new once daily antiretroviral drug, POSTGRADUATE MEDICAL JOURNAL, Vol: 82, Pages: 343-346, ISSN: 0032-5473
- Author Web Link
- Cite
- Citations: 5
Mazhar D, Stebbing J, Lewis R, et al., 2006, The management of meningeal lymphoma in patients with HIV in the era of HAART: intrathecal depot cytarabine is effective and safe, BLOOD, Vol: 107, Pages: 3412-3414, ISSN: 0006-4971
- Author Web Link
- Cite
- Citations: 12
Stebbing J, Gazzard B, Bower M, 2006, The host control of lytic and latent infection with human herpesvirus-8, Journal of Infectious Diseases, Vol: 193, Pages: 1051-1053, ISSN: 0022-1899
de Jager J, Stebbing J, 2006, Erlotinib or capecitabine with gemcitabine in pancreatic cancer?, Future Oncol, Vol: 2, Pages: 161-163, ISSN: 1479-6694
Mazhar D, Stebbing J, Bower M, 2006, Non-Hodgkin's lymphoma and the CNS: prophylaxis and therapy in immunocompetent and HIV-positive individuals, EXPERT REVIEW OF ANTICANCER THERAPY, Vol: 6, Pages: 335-341, ISSN: 1473-7140
- Author Web Link
- Cite
- Citations: 10
Stebbing J, Mazhar D, Lewis R, et al., 2006, The presentation and survival of patients with non-cutaneous AIDS-associated Kaposi's sarcoma, ANNALS OF ONCOLOGY, Vol: 17, Pages: 503-506, ISSN: 0923-7534
- Author Web Link
- Cite
- Citations: 12
Makis AC, Hatzimichael EC, Stebbing J, et al., 2006, C-reactive protein and vascular cell adhesion molecule-1 as markers of severity in sickle cell disease, ARCHIVES OF INTERNAL MEDICINE, Vol: 166, Pages: 366-368, ISSN: 0003-9926
- Author Web Link
- Cite
- Citations: 17
Stebbing J, Dancey G, Bower M, 2006, A tale of three Hs: HPV, HIV & HAART., Future Oncol, Vol: 2, Pages: 1-9, ISSN: 1479-6694
Stebbing J, Bower M, Gazzard B, 2006, New concepts in anti-HIV therapies, New Concepts of Antiviral Therapy, Pages: 189-212, ISBN: 9780387310466
Fewer than one million HIV infected individuals are currently receiving antiretroviral therapy. The limitations of such treatment have underscored the need to develop more effective strategies to control the spread and pathogenesis of infection. In 1996, the era of highly active anti-retroviral therapy (HAART) commenced in established market economies, causing a dramatic reduction in morbidity and mortality in those infected individuals who received these medicines. These agents target aspects of the viral life cycle and there are now 20 approved therapeutic agents for licensed for treatment of infection with the human immunodeficiency virus (HIV), a pathogen that in the 1980s was uniformly fatal. These advances have been associated with significant toxicities and drug resistance. Antiviral potency and durability causing suppression of viremia has been the cornerstone of the initial success of HAART regimens. Following this, the restoration of immune function, the prevention of the emergence of resistance, and ultimately the prevention of disease progression has been the focus of treatment. Future progress will allow greater choices for physicians and patients.
Bower M, Thomson G, Stebbing J, 2006, AIDS-related cancers, Part II: Systemic and cerebral lymphomas, Community Oncology, Vol: 3, Pages: 34-42, ISSN: 1548-5315
Part I of this article, published last month, covered the epidemiology and management of Kaposi's sarcoma and cervical cancer. In this issue, the epidemiology and management of systemic AIDS-related lymphoma and primary cerebral lymphoma are detailed. © 2006 Elsevier Inc. All rights reserved.
Stebbing J, Bower M, 2006, Comparative pharmacogenomics of antiretroviral and cytotoxic treatments, LANCET ONCOLOGY, Vol: 7, Pages: 61-68, ISSN: 1470-2045
- Author Web Link
- Cite
- Citations: 8
Winston A, Hatzimichael E, Marvin V, et al., 2006, Host pharmacogenetics in the treatment of HIV and cancer., Curr Drug Saf, Vol: 1, Pages: 107-116, ISSN: 1574-8863
Physicians prescribing drugs are routinely confronted with the balance between efficacy and toxicity. Pharmacogenetics involves the study of how inheritance influences response to drugs, and its goal is to enable the appropriate selection of these individuals, thus eliminating unpredictable responses. Pharmacogenetics can be used to identify target populations that either will have minimal benefit or a better outcome including better survival or improvement in surrogate end points. As we move towards common use of targeted therapies, the future of medicine will involve an examination of the interplay between multiple genetic factors, as the response to drugs is likely to be complex and polyfactorial especially in chronic diseases. There has already been some success in situations where single genes play a large role in the overall drug response, and this is discussed with reference to commonly used cytotoxics and anti-retrovirals, encompassing the major principles of pharmacogenetics.
Phillips S, Barr A, Wilson E, et al., 2006, Two cases of retroperitoneal haematoma caused by interaction between antibiotics and warfarin, EMERGENCY MEDICINE JOURNAL, Vol: 23, Pages: E8-U135, ISSN: 1472-0205
- Author Web Link
- Cite
- Citations: 7
Stebbing J, Mandalia S, Palmieri C, et al., 2005, Burkitt's lymphoma and previous AIDS-defining illnesses are not prognostic factors in AIDS-related non-Hodgkin's lymphoma, JOURNAL OF CLINICAL ONCOLOGY, Vol: 23, Pages: 8538-8540, ISSN: 0732-183X
- Author Web Link
- Cite
- Citations: 5
Stebbing J, Waters L, Davies L, et al., 2005, Incidence of cancer in individuals receiving chronic zopiclone or eszopiclone requires prospective study, JOURNAL OF CLINICAL ONCOLOGY, Vol: 23, Pages: 8134-8136, ISSN: 0732-183X
- Author Web Link
- Cite
- Citations: 9
Stebbing J, Hatzimichael E, Bower M, et al., 2005, The rationale and development of new drugs to treat HIV infection., Med Chem, Vol: 1, Pages: 635-642, ISSN: 1573-4064
Fewer than one million HIV infected individuals are currently receiving antiretroviral therapy. Present antiretroviral therapy costs between 10,000 dollars and 20,000 dollars per year, which provides excellent value for money in developed countries with a cost of about 10,000 dollars per life year saved; this compares very favourably with other therapies in chronic use. Recent studies have demonstrated a dramatic decline in HIV and AIDS related morbidity and mortality across developed countries and these reductions have been sustained since the introduction of highly active antiretroviral therapy (HAART) since 1996. The use of HAART has been associated with specific toxicities related to the drug class, problems with adherence with the subsequent emergence of viral isolates and resistance associated mutations. The replacement of older therapies with newer drugs that avoid cross resistance even within the same class of antiretroviral, represents a new hope in retroviral targeting.
Jones R, Sawleshwarkar S, Michailidis C, et al., 2005, Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone, HIV MEDICINE, Vol: 6, Pages: 396-402, ISSN: 1464-2662
- Author Web Link
- Cite
- Citations: 49
Stebbing J, Waters L, Mandalia S, et al., 2005, Hepatitis C virus infection in HIV type 1-infected individuals does not accelerate a decrease in the CD4<SUP>+</SUP> cell count but does increase the likelihood of AIDS-defining events, CLINICAL INFECTIOUS DISEASES, Vol: 41, Pages: 906-911, ISSN: 1058-4838
- Author Web Link
- Cite
- Citations: 33
Stebbing J, 2005, Approaches for therapeutic vaccination in HIV infection., J HIV Ther, Vol: 10, Pages: 46-47, ISSN: 1462-0308
Stebbing J, Sawleshwarkar S, Michailidis C, et al., 2005, Assessment of the efficacy of total lymphocyte counts as predictors of AIDS defining infections in HIV-1 infected people, POSTGRADUATE MEDICAL JOURNAL, Vol: 81, Pages: 586-588, ISSN: 0032-5473
- Author Web Link
- Cite
- Citations: 14
Panteli KE, Hatzimichael ECS, Bouranta PK, et al., 2005, Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases, BRITISH JOURNAL OF HAEMATOLOGY, Vol: 130, Pages: 709-715, ISSN: 0007-1048
- Author Web Link
- Cite
- Citations: 102
Bower M, Gazzard B, Mandalia S, et al., 2005, A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy, ANNALS OF INTERNAL MEDICINE, Vol: 143, Pages: 265-273, ISSN: 0003-4819
- Author Web Link
- Cite
- Citations: 88
Waters L, Stebbing J, Jones R, et al., 2005, The effect of statins on HIV rebound and blips, JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, Vol: 39, Pages: 637-638, ISSN: 1525-4135
- Author Web Link
- Cite
- Citations: 17
Waters L, Stebbing J, Mandalia S, et al., 2005, Hepatitis C infection is not associated with systemic HIV-associated non-Hodgkin's lymphoma: A cohort study, INTERNATIONAL JOURNAL OF CANCER, Vol: 116, Pages: 161-163, ISSN: 0020-7136
- Author Web Link
- Cite
- Citations: 21
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.